Jason R. Kelly Sells 219,089 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) insider Jason R. Kelly sold 219,089 shares of the firm’s stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $2.42, for a total transaction of $530,195.38. Following the completion of the transaction, the insider now directly owns 20,943,617 shares in the company, valued at $50,683,553.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ginkgo Bioworks Price Performance

Shares of DNA stock opened at $2.19 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.71 and a quick ratio of 11.78. The firm’s 50-day moving average is $2.80 and its two-hundred day moving average is $2.84. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $1.96 and a 12 month high of $13.74. The company has a market capitalization of $3.91 billion, a PE ratio of -0.96 and a beta of 0.89.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BTIG Research decreased their price target on shares of Ginkgo Bioworks to $4.00 in a research note on Thursday. Raymond James decreased their price target on shares of Ginkgo Bioworks from $14.50 to $10.50 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley assumed coverage on shares of Ginkgo Bioworks in a research note on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.55.

Hedge Funds Weigh In On Ginkgo Bioworks

A number of institutional investors have recently bought and sold shares of DNA. ARK Investment Management LLC raised its stake in Ginkgo Bioworks by 45.2% during the third quarter. ARK Investment Management LLC now owns 126,818,856 shares of the company’s stock worth $395,675,000 after purchasing an additional 39,460,799 shares during the period. Baillie Gifford & Co. raised its stake in shares of Ginkgo Bioworks by 22.4% in the 2nd quarter. Baillie Gifford & Co. now owns 205,327,786 shares of the company’s stock valued at $488,680,000 after acquiring an additional 37,575,106 shares during the period. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at approximately $52,022,000. State Street Corp raised its stake in shares of Ginkgo Bioworks by 210.3% in the 2nd quarter. State Street Corp now owns 12,411,855 shares of the company’s stock valued at $29,540,000 after acquiring an additional 8,411,787 shares during the period. Finally, Nikko Asset Management Americas Inc. raised its stake in shares of Ginkgo Bioworks by 46.5% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 21,858,173 shares of the company’s stock valued at $52,678,000 after acquiring an additional 6,937,185 shares during the period. 53.37% of the stock is owned by hedge funds and other institutional investors.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.